Durable remission attained by long-term brentuximab vedotin administration in a relapsed post-allogeneic bone marrow transplant Hodgkin lymphoma patient

DOI Web Site PubMed
  • ONO Yuichiro
    Department of Hematology, Kobe City Medical Center General Hospital
  • HIRAMOTO Nobuhiro
    Department of Hematology, Kobe City Medical Center General Hospital
  • YOSHIOKA Satoshi
    Department of Hematology, Kobe City Medical Center General Hospital
  • YABUSHITA Tomohiro
    Department of Hematology, Kobe City Medical Center General Hospital
  • KOBA Yusuke
    Department of Hematology, Hyogo Prefectural Amagasaki Hospital
  • TABATA Sumie
    Department of Hematology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute
  • IMAI Yukihiro
    Department of Clinical Pathology, Kobe City Medical Center General Hospital
  • ISHIKAWA Takayuki
    Department of Hematology, Kobe City Medical Center General Hospital

Bibliographic Information

Other Title
  • Brentuximab vedotin長期投与により長期寛解を維持できた同種骨髄造血幹細胞移植後再発Hodgkinリンパ腫
  • 症例報告 Brentuximab vedotin長期投与により長期寛解を維持できた同種骨髄造血幹細胞移植後再発Hodgkinリンパ腫
  • ショウレイ ホウコク Brentuximab vedotin チョウキ トウヨ ニ ヨリ チョウキカンカイ オ イジ デキタ ドウシュ コツズイ ゾウケツ カンサイボウ イショク ゴ サイハツ Hodgkin リンパシュ

Search this article

Abstract

<p>The prognosis for relapsed Hodgkin lymphoma after allogeneic hematopoietic cell transplantation (HSCT) is poor, partly because of limited treatment options. Here we present a case of a Hodgkin lymphoma patient who relapsed after allogeneic HSCT but remains in complete remission (CR) at 38 months from the start of extended brentuximab vedotin (BV) dosing. A 33-year-old man with refractory and relapsed nodular sclerosis classical Hodgkin lymphoma who underwent previous treatments, including adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) ; seven combination regimens; and autologous HSCT, prior to allogeneic HSCT achieved CR after three cycles of BV. BV was continued for 26 cycles and then discontinued because of a neurogenic bladder. The other adverse effects were mild paresthesia in the fingers, mild dysgeusia, and fatigue. The patient still remains in CR at 38 months from the start of BV. Thus, extended BV dosing may be a treatment option for relapsed and refractory Hodgkin lymphoma after allogeneic HSCT.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 58 (12), 2397-2401, 2017

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top